Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China
· Delayed Price · Currency is CNY 12.40
-0.32 (-2.52%)
Feb 28, 2025, 2:45 PM CST
SHA:603707 Revenue
Nanjing King-Friend Biochemical Pharmaceutical had revenue of 945.35M CNY in the quarter ending September 30, 2024, with 12.79% growth. This brings the company's revenue in the last twelve months to 3.88B, down -3.15% year-over-year. In the year 2023, Nanjing King-Friend Biochemical Pharmaceutical had annual revenue of 3.93B with 5.89% growth.
Revenue (ttm)
3.88B
Revenue Growth
-3.15%
P/S Ratio
5.11
Revenue / Employee
2.67M
Employees
1,451
Market Cap
20.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.93B | 218.67M | 5.89% |
| Dec 31, 2022 | 3.71B | 26.03M | 0.71% |
| Dec 31, 2021 | 3.69B | 771.81M | 26.48% |
| Dec 31, 2020 | 2.91B | 445.21M | 18.03% |
| Dec 31, 2019 | 2.47B | 769.34M | 45.25% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Mindray Bio-Medical Electronics | 37.11B |
| Jiangsu Hengrui Medicine | 26.00B |
| WuXi AppTec | 38.50B |
| Aier Eye Hospital Group | 20.62B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
| Shanghai United Imaging Healthcare | 10.93B |
| Yunnan Baiyao Group Co.,Ltd | 39.34B |
| Sichuan Biokin Pharmaceutical | 5.85B |